terry j. opgenorth abbott laboratories academic-industry collaboration terry j. opgenorth abbott...
TRANSCRIPT
Academic-Industry CollaborationTerry J. OpgenorthTerry J. Opgenorth
Abbott LaboratoriesAbbott Laboratories
The Development of Endothelin Receptor Antagonists for the Treatment of Prostate Cancer
Lessons for Career Development
Career Preparation for Industry
• search Out presentations/abstracts from biotech and pharma companies
• read pharmacology journals
• correspond with authors – request compounds– Proposal – mutual benefit => “collaborate”
1996: Atrasentan publication
54 publications(18 Abbott-only authors)
Nelson Lab15 pubs/6 with Abbott
Bagnatto Lab15 pubs/3 with Abbott
1995: Bagnatto LabET mitogenic/cancer
1995 (Dec): Candidate Declared 1995: J. Nelson
Prostate Cancer Hypothesis
1993-4: Lepor Lab3 pubs - Prostate
To 1995: 30 publications(24 Abbott-only authors)
1990: 2 Abbott ET
publications
1988: Discovery of Endothelin
Abbott ET Project Begins
ACADEMIA ACADEMIAINDUSTRY
Wall Street Journal – May 14, 2001
“An Abbott VP happened to be in the audience and soon got Dr. Nelson together with Abbott researchers working on the endothelin program…”
“…a compound in search of disease….We were planning to bring if forward as a cardiovascular agent”
J. Clin. Oncol. 21: 679-689, 2003
Abbott & Hopkins researchers are primary authors
Nat. Rev. Cancer 3: 110-116, 2003
Abbott
Rome
Laval U.
U. Pitt.
Physiologists in Pharma and Biotech Research
Physiologist•Molecular•Cell•Organ•Animal
Pharmacologist
•Molecular•Cell•Organ•Animal
IntegrativeSystems
Drug Discovery
Drug
DRC
Career Preparation for Industry
• search Out presentations/abstracts from biotech and pharma companies
• read pharmacology journals
• correspond with authors – request compounds– Proposal – mutual benefit => “collaborate”